Literature DB >> 8916940

Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor.

D E Hogge1, P M Lansdorp, D Reid, B Gerhard, C J Eaves.   

Abstract

To determine whether the sensitivity of the human long-term culture-initiating cell (LTC-IC) assay could be increased, we have evaluated a spectrum of different fibroblast cell lines for their abilities to influence the number of cells detectable as LTC-IC, to influence LTC-IC maintenance, and/or to influence LTC-IC differentiation into colony-forming cells (CFC) in cocultures containing various sources of LTC-IC. In a series of initial experiments with highly purified subpopulations of CD34+ cells from normal human marrow, no significant difference could be found between any of 3 different murine stromal fibroblast cells in terms of their support of either LTC-IC detection (CFC production) or maintenance (over a 6-week period), and all were equivalent to primary human marrow feeders (HMF). On the other hand, murine M2-10B4 fibroblasts engineered to produce high levels of both human granulocyte colony-stimulating factor (G-CSF) and interleukin-3 (IL-3; 190 and 4 ng/mL, respectively), either alone or mixed 1:1 with SI/SI fibroblasts engineered to produce high levels of soluble Steel factor (SF), with or without production of the transmembrane form of SF (60 and 4 ng/ mL, respectively), stimulated the production of up to 20-fold more CFC in LTC of cells from normal human marrow, G-CSF-mobilized blood or cord blood when compared with parallel cocultures containing HMF. Limiting dilution analysis of the CFC output from all three sources of LTC-IC showed that most of this increase was due to an ability of the engineered feeders to increase the plating efficiency of the LTC-IC assay (approximately 14-fold for marrow LTC-IC and approximately 4-fold for cord blood or mobilized blood LTC-IC). Analysis of the phenotype of these additionally recruited LTC-IC from marrow showed they had the same primitive CD34+CD45RA-CD71- phenotype as conventionally defined LTC-IC. The limiting dilution studies also showed that the average number of CFC produced per LTC-IC was additionally and independently increased to yield values of 18 CFC per LTC-IC in marrow, 28 for LTC-IC in cord blood, and 25 for LTC-IC in G-CSF-mobilized blood. Replating of cells from primary LTC with different feeders into secondary LTC-IC assays containing the best combination of engineered feeders showed that LTC-IC maintenance could be significantly enhanced (up to 7-fold as compared with primary cocultures containing HMF). However, this enhancement was still not sufficient to amplify the number of LTC-IC present after 6 weeks above the input value. Thus, engineering murine fibroblasts to produce sufficient SF, G-CSF, and IL-3 can markedly enhance the detection as well as the maintenance in vitro of a very primitive population of human progenitor cells present in normal adult marrow, mobilized blood, and cord blood by providing the most sensitive assay conditions thus far described. The present findings also provide new evidence of biologic heterogeneity between different cell populations that can be operationally identified as LTC-IC, thus re-emphasizing the importance of limiting dilution analyses to distinguish between quantitative and qualitative effects on these cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916940

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Cell cycle distribution of primitive haematopoietic cells stimulated in vitro and in vivo.

Authors:  X W Zhang; J Audet; J M Piret; Y X Li
Journal:  Cell Prolif       Date:  2001-10       Impact factor: 6.831

2.  Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice.

Authors:  E Conneally; J Cashman; A Petzer; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Authors:  Marcus Järås; Petra Johnels; Nils Hansen; Helena Agerstam; Panagiotis Tsapogas; Marianne Rissler; Carin Lassen; Tor Olofsson; Ole Weis Bjerrum; Johan Richter; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

4.  Biophysical differences between chronic myelogenous leukemic quiescent and proliferating stem/progenitor cells.

Authors:  Nataliia V Guz; Sapan J Patel; Maxim E Dokukin; Bayard Clarkson; Igor Sokolov
Journal:  Nanomedicine       Date:  2016-07-16       Impact factor: 5.307

5.  Expansion of engrafting human hematopoietic stem/progenitor cells in three-dimensional scaffolds with surface-immobilized fibronectin.

Authors:  Qi Feng; Chou Chai; Xue-Song Jiang; Kam W Leong; Hai-Quan Mao
Journal:  J Biomed Mater Res A       Date:  2006-09-15       Impact factor: 4.396

6.  Expansion of human SCID-repopulating cells under hypoxic conditions.

Authors:  Guénahel H Danet; Yi Pan; Jennifer L Luongo; Dominique A Bonnet; M Celeste Simon
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

7.  Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

Authors:  Jennifer H Law; Yvonne Li; Karen To; Michelle Wang; Arezoo Astanehe; Karen Lambie; Jaspreet Dhillon; Steven J M Jones; Martin E Gleave; Connie J Eaves; Sandra E Dunn
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

8.  C1qRp defines a new human stem cell population with hematopoietic and hepatic potential.

Authors:  Guenahel H Danet; Jennifer L Luongo; Gary Butler; Min Min Lu; Andrea J Tenner; M Celeste Simon; Dominique A Bonnet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-24       Impact factor: 11.205

9.  Molecular profiling reveals similarities and differences between primitive subsets of hematopoietic cells generated in vitro from human embryonic stem cells and in vivo during embryogenesis.

Authors:  Giorgia Salvagiotto; Yun Zhao; Maxim Vodyanik; Victor Ruotti; Ronald Stewart; Marco Marra; James Thomson; Connie Eaves; Igor Slukvin
Journal:  Exp Hematol       Date:  2008-10       Impact factor: 3.084

10.  A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

Authors:  Daniel J Goff; Angela Court Recart; Anil Sadarangani; Hye-Jung Chun; Christian L Barrett; Maryla Krajewska; Heather Leu; Janine Low-Marchelli; Wenxue Ma; Alice Y Shih; Jun Wei; Dayong Zhai; Ifat Geron; Minya Pu; Lei Bao; Ryan Chuang; Larisa Balaian; Jason Gotlib; Mark Minden; Giovanni Martinelli; Jessica Rusert; Kim-Hien Dao; Kamran Shazand; Peggy Wentworth; Kristen M Smith; Christina A M Jamieson; Sheldon R Morris; Karen Messer; Lawrence S B Goldstein; Thomas J Hudson; Marco Marra; Kelly A Frazer; Maurizio Pellecchia; John C Reed; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.